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The fibroblast growth factor (FGF) family comprises 22 members with diverse functions in
development and metabolism. Fgf20 was originally identified as a new Fgf preferentially
expressed in the substantia nigra pars compacta (SNpc). Fgf20, which acts on proximal
cells, significantly enhanced the survival of cultured dopaminergic neurons by activating
the mitogen-activated protein kinase (MAPK) pathway through Fgf receptor 1c. In the
rat model of Parkinson’s disease, Fgf20 afforded significant protection against the
loss of dopaminergic neurons. The significant correlation of Parkinson’s disease with
single-nucleotide polymorphisms in FGF20 indicates that the genetic variability of FGF20
can be a Parkinson’s disease risk. Neural and embryonic stem (ES) cells have been
considered as cell resources for restorative transplantation strategies in Parkinson’s
disease. Fgf20 promoted the differentiation of these stem cells into dopaminergic
neurons, which attenuated neurological symptoms in animal models of Parkinson’s
disease. These findings indicate the importance of FGF20 for the differentiation and
survival of dopaminergic neurons and the etiology and therapy of Parkinson’s disease.
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INTRODUCTION
Fibroblast growth factors (FGFs) are polypeptides with diverse
functions in development, metabolism, and neural activities. The
FGF family comprises 22 members, which have been classified as
paracrine, endocrine, and intracrine FGFs by their mechanisms
of action. Most FGFs are paracrine FGFs that act as local sig-
naling molecules (Itoh and Ornitz, 2011). Fgf20 was originally
identified as a new Fgf preferentially expressed in the substantia
nigra pars compacta (SNpc). Fgf20, a paracrine Fgf, with neu-
rotrophic activity in cultured dopaminergic neurons (Ohmachi
et al., 2000, 2003) has been suggested to play important roles in
the development of dopaminergic neurons (Grothe et al., 2004;
Takagi et al., 2005; Correia et al., 2007; Shimada et al., 2009). In
addition, FGF20mutations may result in Parkinson’s disease (van
der Walt et al., 2004; Satake et al., 2007; IPDGC, 2011; Pan et al.,
2012; Pihlstrøm et al., 2013; Wang et al., 2013). As these find-
ings indicate that FGF20 may provide useful clues on the etiology
and therapy of Parkinson’s disease, a succinct review on the roles
of FGF20 in dopaminergic neurons and Parkinson’s disease has
been provided. In this review, we refer to the human and rodent
orthologs as FGF20 and Fgf20 according to the Human Genome
Organization and the Mouse Genome Informatics, respectively.
IDENTIFICATION OF FGF20
Fgf20, originally identified in the rat brain, encodes a secreted
protein of 212 amino acids (Ohmachi et al., 2000). The FGF
gene family comprising 22 members has been classified into
7 subfamilies; FGF/1/2, FGF4/5/6, FGF3/7/10/22, FGF8/17/18,
FGF9/16/20, FGF11/12/13/14, and FGF19/21/23. FGF20 is a
member of the FGF9/16/20 subfamily, which is a paracrine Fgf
(Figure 1) (Itoh and Ornitz, 2011).
FGF20 IN DOPAMINERGIC NEURON SURVIVAL
As paracrine FGFs are local signal molecules, Fgf20 is expected to
act on dopaminergic neurons in the SNpc in a paracrine man-
ner. However, as both Fgf20 and Fgfr1 are expressed in most
dopaminergic neurons in the SNpc, Fgf20 may act on them
in an autocrine/paracrine manner. Fgf20 was shown to signifi-
cantly enhance the survival of cultured rat dopaminergic neurons
(Ohmachi et al., 2000, 2003).
Paracrine FGF signaling is mediated by the activation of FGFR.
Paracrine FGFs bind to FGFRs and induce the phosphoryla-
tion of specific cytoplasmic tyrosine residues, which triggers the
activation of cytoplasmic signal transduction pathways. Major
FGF/FGFR-dependent signaling was shown to be mediated by the
mitogen-activated protein kinase (MAPK) and phospholipase-Cγ
pathways (Thisse and Thisse, 2005).
FGFRs are receptor tyrosine kinases with an extracellular
ligand-binding domain, which comprises three immunoglobulin-
like domains (I, II, and III). There are seven major FGFR proteins
including FGFRs1b, 1c, 2b, 2c, 3b, 3c, and 4, which are generated
from four functional FGFR genes, FGFR1–FGFR4 by alternative
splicing (Zhang et al., 2006). Fgfr1c is abundantly expressed in
dopaminergic neurons in the SNpc. Fgf20 binds to Fgfr1c with
high affinity. Experiments with the Fgfr inhibitor SU5402 or
MAPK pathway inhibitor PD98059 indicate that activation of the
MAPK pathway by Fgf20 through Fgfr1c is essential for the sur-
vival of dopaminergic neurons in the SNpc (Figure 2) (Ohmachi
et al., 2003).
Calbindin-negative dopaminergic neurons are preferentially
lost in Parkinson’s disease. Fgf20 almost completely rescued
rat calbindin-negative midbrain dopaminergic neurons from
the toxicity of 6-hydroxyldopamine and stress-induced cytosolic
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FIGURE 1 | Evolutionary relationships within the human FGF gene
family by phylogenetic analysis. Phylogenetic analysis suggests that 22
FGF genes can be arranged into seven subfamilies containing two to four
members each. Branch lengths are proportional to the evolutionary
distance between each gene.
FIGURE 2 | Action mechanism of FGF20 on dopaminergic neurons.
FGF20 acts on dopaminergic neurons in a paracrine manner. FGF20 binds to
FGFR1c and the phosphorylation of specific cytoplasmic tyrosine residues.
The phosphorylation of FGFR1c triggers activation of the MPAK pathway,
which plays important roles in the survival of dopaminergic neurons.
dopamine, and promoted dopamine release in calbindin-negative
dopaminergic neurons by activating Fgfr1 followed by its down-
stream cascade activation. These results show that Fgf20 protects
the specific midbrain neuron type at most risk in Parkinson’s
patients (Murase and McKay, 2006).
In the unilateral, 6-hydroxydopamine lesion rat model of
Parkinson’s disease, supranigral infusion of Fgf20 afforded sig-
nificant protection against the loss of dopaminergic neurons in
the SNpc and striatum. Protection of the nigrostriatal tract was
accompanied by the significant preservation of gross locomotion
and fine motor movements and the reversal of apomorphine-
induced contraversive rotations. These results imply the potential
neuroprotective role of Fgf20 in this disease (Sleeman et al., 2012).
FGF20 IN PARKINSON’S DISEASE
Parkinson’s disease is a common neurodegenerative disorder.
The inability to control movement in patients with this disease
has been attributed to the severe loss of dopaminergic neurons
within the substantia nigra. Environmental and genetic sources
act together in the disease cascade.
FGF20 has been mapped to 8p21.3–8p22, which is within
an area of Parkinson’s disease linkage. To test whether FGF20
genetic variability was a risk factor for Parkinson’s disease, five
single-nucleotide polymorphisms (SNPs) lying in FGF20 were
examined in a large family study. The highly significant cor-
relation of Parkinson’s disease with one SNP located in the
intron and two SNPs in the 3′ regulatory region was revealed,
which indicated that Fgf20 genetic variability is a risk factor
for Parkinson’s disease (van der Walt et al., 2004). In addi-
tion, FGF20 genetic variability was shown to be a risk factor for
Parkinson’s disease in Japanese and Chinese populations (Satake
et al., 2007; Pan et al., 2012), while, was not a risk factor for
Parkinson’s disease in Finnish and Greek populations (Clarimon
et al., 2005). The discrepancy between these results remains to be
elucidated.
The SNP in the 3′ non-coding region of FGF20 can be a risk
factor for Parkinson’s disease. The risk allele disrupts a bind-
ing site for microRNA-433, increasing FGF20 mRNA translation.
This increase in FGF20 mRNA translation has been correlated
with increased α-synuclein expression. As α-synuclein is the prin-
cipal component of filamentous Lewy bodies, the defining patho-
logical hallmark of Parkinson’s disease, these findings suggest
a novel mechanism of action for the risk of Parkinson’s dis-
ease (Wang et al., 2008). In addition, FGF20 and α-synuclein
were also shown to be associated with sporadic Parkinson’s dis-
ease (Mizuta et al., 2008). However, no association between the
SNP in FGF20, microRNA-433, or α-synuclein expression and
Parkinson’s disease have been reported (Wider et al., 2009; de
Mena et al., 2010). The discrepancy between these results remains
to be elucidated.
The genetic variability of the monoamine oxidase B gene
(MAOB) has also been suggested as a risk factor for Parkinson’s
disease. Both FGF20 and MAOB are in the dopamine bio-
pathway. SNP variants in FGF20 and MAOB show evidence of
statistical interactions, which emphasizes the importance of con-
sidering them jointly in the genetic analysis of Parkinson’s disease,
and illustrates the potential patterns of biological interactions
contributing to the risk of Parkinson’s disease (Gao et al., 2008).
A genome-wide association study (GWAS) to examine many
common genetic variants was conducted in different individuals
to identify any variant associated with a trait. The GWAS typically
focused on associations between SNPs and traits such as major
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diseases. FGF20 was shown to be a risk factor for Parkinson’s dis-
ease by the GWAS (IPDGC, 2011; Pihlstrøm et al., 2013; Wang
et al., 2013).
FGF20 IN THE NEURAL DIFFERENTIATION OF STEM CELLS
INTO DOPAMINERGIC NEURONS
Neural stem (NS) cells are multipotent cells characterized by
their capability to differentiate into neurons, astrocytes, and
oligodendrocytes, and have been considered as cell resources
for restorative transplantation strategies in Parkinson’s disease.
Nurr1 is a transcription factor of the thyroid hormone/retinoic
acid nuclear receptor superfamily that is required for the induc-
tion of dopaminergic neurons. However, Nurr1 alone is not
sufficient to induce a dopaminergic phenotype in NS cells. A
co-culture ofNurr1-transfected NS cells with Schwann cells over-
expressing Fgf20 was shown to induce dopaminergic neurons in
NS cells. Differentiated Nurr1-NS cells retained both neuronal
morphology and tyrosine hydroxylase expression after transplan-
tation into the striatum of 6-hydroxydopamine-lesioned rats.
However, neuritogenesis was only observed after postnatal grafts.
These results suggest that Fgf20 promotes the differentiation of
Nurr1-NS cells into dopaminergic neurons and that additional
factors are required for the efficient differentiation of dopamin-
ergic neurons in the adult brain (Grothe et al., 2004).
Embryonic stem (ES) cells are pluripotent cells derived from
the inner cell mass of the preimplantation blastocyst. These cells
have many of the characteristics required of a cell source for
cell-replacement therapy, including proliferation and differenti-
ation capacities. ES cells are also promising donor cell sources for
cell-replacement therapy in Parkinson’s disease. FGF20 acts syn-
ergistically with FGF2 to increase the number of dopaminergic
neurons in primate ES cell–derived neurospheres composed of
neural progenitors. Dopaminergic neurons generated from pri-
mate ES cells were transplanted into 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine–treated (MPTP-treated) primates, a primate
model for Parkinson’s disease. Behavioral studies and functional
imaging revealed that the transplanted dopaminergic cells func-
tioned as dopaminergic neurons and attenuated MPTP-induced
neurological symptoms (Takagi et al., 2005).
Parthenogenesis has attracted attention as an alternative
method to derive ES cells that does not involve the destruction of
viable embryos. Transplantation of dopaminergic neurons gener-
ated from parthenogenetic primate ES cells restored motor func-
tion in hemi-Parkinsonian, 6-hydroxy-dopamine-lesioned rats.
Exposure to FGF20, along with WNT5a and FGF2, at the final
stage of in vitro differentiation enhanced the maturation and
in vivo survival of dopaminergic neurons and, correspondingly,
the extent of motor recovery in transplanted animals (Sanchez-
Pernaute et al., 2008). Induced pluripotent stem (iPS) cell-derived
dopaminergic neurons were also shown to integrate into the stria-
tum of Parkinsonian rats with behavioral improvements (Gibson
et al., 2012). However, experiments on iPS cells using FGF20 have
not been reported.
Neuronal differentiation in human ES cells was induced by
co-culturing with PA6 mouse stromal cells. The number of tyro-
sine hydroxylase-expressing neurons significantly increased in
culture medium supplemented with FGF20. Cultured cells also
expressed other midbrain dopaminergic markers, which suggests
that some differentiate into midbrain dopaminergic neurons.
However, FGF20 has no effect on the size of the soma area or neu-
rite length of dopaminergic neurons. FGF20 significantly reduced
the proportion of cells undergoing cell death. These results indi-
cate that FGF20 specifically increased the yield of dopaminergic
neurons from human ES cells grown on PA6 feeder cells, and
at least part of this effect was due to a reduction in cell death
(Correia et al., 2007). In addition, FGF20 along with FGF2
enhanced dopaminergic neuron differentiation from human ES
cell-derived neural progenitor cells directly without co-culturing
with PA6 cells (Shimada et al., 2009).
CONCLUSIONS
Fgf20 is expressed in the SNpc of the midbrain. Fgf20 signifi-
cantly enhances the survival of cultured dopaminergic neurons
in a paracrine manner. In the rat model of Parkinson’s disease,
Fgf20 affords significant protection against the loss of dopamin-
ergic neurons. The significant correlation of Parkinson’s disease
with SNPs within FGF20 indicated that FGF20 genetic variability
is a risk factor for Parkinson’s disease. Fgf20 promotes differentia-
tion of cultured cells into dopaminergic neurons, and attenuated
neurological symptoms in animal models of Parkinson’s disease.
These findings indicate the importance of FGF20 in both the
differentiation and survival of dopaminergic neurons and the
etiology and therapy of Parkinson’s disease. Further studies on
FGF20 will provide useful clues on the etiology and therapy of
Parkinson’s disease.
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